All In MedTech

Device Trial Radar · NCT04226547

Amplatzer Amulet LAAO vs. NOAC

Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 2,650 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,650

Planned (sponsor's estimate)

Start

Jul 7, 2020

Primary completion

Jan 2029

Study completion Apr 2031

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Jan 13, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.

Conditions

  • Atrial Fibrillation
  • Stroke
  • Bleeding

Interventions

  • Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)Device

    Implantation of an Amplatzer Amulet left atrial appendage occluder

  • Non-Vitamin K Oral AntagonistsDrug

    Initiation or continuation of a NOAC drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of ischemic stroke, systemic embolism, or cardiovascular (CV) mortalityTime frame: 2 years
  2. Major bleeding or clinically relevant non-major bleeding (CRNMB) events, excluding procedure related eventsTime frame: 2 years
  3. Composite of ischemic stroke or systemic embolismTime frame: 3 years

Locations

127 sites in 16 countries. Site status is shown where the registry gives one.

  • University Hospital - Univ. of Alabama at Birmingham (UAB)

    Birmingham, Alabama

  • Heart Center Research, LLC

    Huntsville, Alabama

  • Arizona Cardiovascular Research Center

    Phoenix, Arizona

124 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.